Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (3): 323-325    DOI: 10.31083/j.ejgo.2020.03.5363
Editorial | Next articles
Genomic profiling in gynaecological oncology: the future is now!
Luca Roncati1(), Maria Vadalà2, Pepe Valentina2, Veronica Corazzari2, Beniamino Palmieri2
1University Hospital of Modena, Modena I-41124, Italy
2Second Opinion Network, Modena I-41124, Italy
Download:  PDF(366KB)  ( 297 ) Full text   ( 12 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Nowadays, thanks to next generation sequencing, it is simultaneously possible to search for driver mutations in hundreds of cancer-related genes with high sensibility and specificity, by exploiting formalin-fixed paraffin-embedded tumor material, from biopsy samples and surgical specimens, or circulating tumor DNA in the patient's blood. In addition to indicate the genomic alterations, this modern technology provides information about: the approved therapies in the patient’s cancer type or in other tumor types for a personalized oncology; potential clinical trials; mutational burden and microsatellite instability (MSI). This last datum is particularly relevant because the U.S. Food & Drug Administration (FDA) has approved the use of pembrolizumab for all unresectable or metastatic, MSI-high or mismatch repair deficient, solid malignancies, among which there are 17-32% of sporadic endometrial carcinomas and 10-17% of sporadic ovarian cancers. Similarly, the FDA has approved olaparib for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, characterized by deleterious or suspected deleterious germline or somatic mutations in ‘breast cancer’ (BRCA) genes, who are in complete or partial response to first-line platinum-based chemotherapy. Therefore, we are facing an era of innovation in gynaecological oncology, in which molecular profiling is joining immunomorphological typing for new health goals.

Key words:  Next generation sequencing (NGS)      Microsatellite instability (MSI)      Mismatch repair (MMR)      Breast cancer (BRCA) genes      Pembrolizumab      Olaparib     
Submitted:  14 September 2019      Accepted:  24 September 2019      Published:  15 June 2020     
*Corresponding Author(s):  Luca Roncati     E-mail:  emailmedical@gmail.com

Cite this article: 

Luca Roncati, Maria Vadalà, Pepe Valentina, Veronica Corazzari, Beniamino Palmieri. Genomic profiling in gynaecological oncology: the future is now!. European Journal of Gynaecological Oncology, 2020, 41(3): 323-325.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.03.5363     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I3/323

Figure 1.  - The WCD logo has been developed by the Union for International Cancer Control (UICC) under a Creative Commons Attribution-ShareAlike 4.0 International License, in order to establish a global identity and to cement the day in calendars and activities around the world.

[1] Dulbecco R.: “A turning point in cancer research: sequencing the human genome”. Science, 1986, 231, 1055.
doi: 10.1126/science.3945817 pmid: 3945817
[2] Collins F.S., Morgan M., Patrinos A.: “The Human Genome Project: lessons from large-scale biology”. Science, 2003, 300, 286.
doi: 10.1126/science.1084564 pmid: 12690187
[3] Covell D.G.: “Data mining approaches for genomic biomarker development: applications using drug screening data from the Cancer Genome Project and the Cancer Cell Line Encyclopedia”. PLoS One, 2015, 10, e0127433.
doi: 10.1371/journal.pone.0127433 pmid: 26132924
[4] Strausberg R.L., Simpson A.J., Old L.J., Riggins G.J.: “Oncogenomics and the development of new cancer therapies”. Nature, 2004, 429, 469.
doi: 10.1038/nature02627 pmid: 15164073
[5] Roncati L., Simoni M., Maiorana A.: “The prognostic value of miRNA146a in follicular thyroid carcinoma”. Med. Oncol., 2013, 30, 703.
doi: 10.1007/s12032-013-0703-8 pmid: 23982677
[6] Roncati L., Barbolini G., Sartori G., Siopis E., Pusiol T., Maiorana A.: “Loss of CDKN2A promoter methylation coincides with the epigenetic transdifferentiation of uterine myosarcomatous cells”. Int. J. Gynecol. Pathol., 2016, 35, 309.
doi: 10.1097/PGP.0000000000000181 pmid: 27276112
[7] Krontiris T.G.: “Oncogenes”. N. Engl. J. Med., 1995, 333, 303.
doi: 10.1056/NEJM199508033330508 pmid: 7596376
[8] Frampton G.M., Fichtenholtz A., Otto G.A., Wang K., Downing S.R., He J., et al.: “Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing”. Nat. Biotechnol., 2013, 31, 1023.
doi: 10.1038/nbt.2696 pmid: 24142049
[9] He J., Abdel Wahab O., Nahas M.K., Wang K., Rampal R.K., Intlekofer A.M., et al.: “Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting”. Blood, 2016, 127, 3004.
doi: 10.1182/blood-2015-08-664649 pmid: 26966091
[10] U.S. Food & Drug Administration. Resources for Information on Approved Drugs. Silver Spring, MD: U.S. Food & Drug Administration; 2017 [accessed 2017 May 30]. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication.
[11] Karamurzin Y., Rutgers J.K.: “DNA mismatch repair deficiency in endometrial carcinoma”. Int. J. Gynecol. Pathol., 2009, 28, 239.
doi: 10.1097/PGP.0b013e31818d8fe6 pmid: 19620942
[12] Murali R., Soslow R.A., Weigelt B.: “Classification of endometrial carcinoma: more than two types”. Lancet Oncol., 2014, 15, e268.
[13] Singer G., Kallinowski T., Hartmann A., Dietmaier W., Wild P.J., Schraml P., et al.: “Different types of microsatellite instability in ovarian carcinoma”. Int. J. Cancer, 2004, 112, 643.
doi: 10.1002/ijc.20455 pmid: 15382045
[14] Shannon C., Kirk J., Barnetson R., Evans J., Schnitzler M., Quinn M., et al.: “Incidence of microsatellite instability in synchronous tumors of the ovary and endometrium”. Clin. Cancer Res., 2003, 9, 1387.
pmid: 12684409
[15] Kobayashi H., Ohno S., Sasaki Y., Matsuura M.: “Hereditary breast and ovarian cancer susceptibility genes (review)”. Oncol. Rep., 2013, 30, 1019.
doi: 10.3892/or.2013.2541
[16] U.S. Food & Drug Administration. Drugs. Silver Spring, MD: U.S. Food & Drug Administration; 2018 [accessed 2018 Dec 26] Available at: https://www.fda.gov/drugs/fda-approved-olaparib-lynparza-astrazeneca-pharmaceuticals-lp-maintenance-treatment-adult-patients.
doi: 10.5740/jaoacint.17-0221 pmid: 28851479
[17] Roncati L., Barbolini G., Piacentini F., Piscioli F., Pusiol T., Maiorana A.: “Prognostic factors for breast cancer: an immunomorphological update”. Pathol. Oncol. Res., 2016, 22, 449.
doi: 10.1007/s12253-015-0024-7 pmid: 26589512
[18] III Convegno Oncologia Integrata. Genetica e medicina integrata in oncologia e psiconcologia: come utilizzare la mappa del nostro DNA per traguardi di prevenzione e salute. Modena, IT: Forum Monzani; 2019 [accessed 2019 Mar 3]. Available at: https://www.convegnoncologiaintegrata.it.
[19] Siegel R.L., Miller K.D., Jemal A.: “Cancer statistics, 2019”. CA Cancer J. Clin., 2019, 69, 7.
doi: 10.3322/caac.21551 pmid: 30620402
[1] E. De Matteis, G. Cormio, E. Naglieri, C. Scavelli, V. Loizzi, P. Cito, M. C. Chetrì, P. Tarantino, E. Mazzoni, G. Ronzino. ReOL – OLaparib in the REal World. A retrospective observational study to evaluate the impact of olaparib on the real-world treatment of BRCA carrier patients with recurrent ovarian cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 759-764.
No Suggested Reading articles found!